Hysingla™ ER (hydrocodone bitartrate) Extended-Release Tablets CII Now ...
Hysingla ER may cause severe hypotension, including orthostatic hypotension and syncope in ambulatory patients. Monitor patients during dose initiation or titration. In patients with circulatory shock, Hysingla ER may cause vasodilation that can ...
SYS-CON Media (press release) - Mon, 26 Jan 2015 06:26

FDA Approval of 'Novel' New Drugs Up Sharply in 2014
Once on the market, the drug must undergo further studies to confirm the clinical benefit. An example from 2014 was droxidopa (Northera, Lundbeck, Inc) for neurogenic orthostatic hypotension. More information about the FDA's approval of novel new drugs ...
Medscape - Thu, 22 Jan 2015 02:52

Exercising in Pregnancy: What Advice Should be Given to Patients?
After the first trimester, pregnant women are often told to avoid supine positions for long periods of time owing to concerns that the gravid uterus may cause venous blood flow obstruction and the potential for orthostatic hypotension. While this ...
Medscape - Thu, 22 Jan 2015 21:15

Vanda Announces Listing of a New FanaptB. Patent in the FDA Orange Book
Prescribers should also consider the need to titrate Fanapt® slowly to avoid orthostatic hypotension, which may lead to delayed effectiveness compared to some other drugs that do not require similar titration. IMPORTANT WARNINGS and PRECAUTIONS: ...
CNNMoney - Fri, 16 Jan 2015 06:26

Vanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book
MarketWatch - Fri, 16 Jan 2015 06:33

FDA Grants Priority Review for Three-Month Paliperidone Palmitate for the ...
Orthostatic Hypotension and Syncope: INVEGA® SUSTENNA® may induce orthostatic hypotension in some patients due to its alpha-blocking activity. INVEGA® SUSTENNA® should be used with caution in patients with known cardiovascular disease, ...
PR Newswire (press release) - Mon, 19 Jan 2015 07:00

Falling into a |dead faint
Orthostatic hypotension imposes, when appropriate, the discontinuation of the responsible medicines and optimal treatment of the predisposing medical condition. The patient should also be informed on how to prevent such an event, for instance moving ...
The Nation - Mon, 19 Jan 2015 09:15

First Neurogenic Orthostatic Hypotension Drug Launched
Lundbeck announced the availability of Northera (droxidopa) capsules for the treatment of orthostatic dizziness and lightheadedness in adult patients with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (eg, ...
Monthly Prescribing Reference - Tue, 02 Sep 2014 08:11

Lundbeck Announces Availability of NORTHERA™ (droxidopa) Capsules in the ...
Business Wire (press release) - Tue, 02 Sep 2014 06:41

Lundbeck launches Northera in USA
The Pharma Letter - Tue, 02 Sep 2014 08:45



FDA Okays Carbidopa/Levodopa ER (Rytary) in Parkinson's
The most common adverse reactions in clinical trials were nausea, dizziness, headache, insomnia, abnormal dreams, dry mouth, dyskinesia, anxiety, constipation, vomiting, and orthostatic hypotension. This product is not for use in patients taking ...
Medscape - Thu, 08 Jan 2015 12:59

FDA Approves Impax Pharmaceutical's Parkinson's Treatment
Drug Discovery & Development - Thu, 08 Jan 2015 05:52

FDA Approves Extended-Release Oral Treatment for Parkinson's Disease
HCPLive - Thu, 08 Jan 2015 09:15

DUAL RELEASE L-DOPA APPROVED FOR PARKINSON'S DISEASE
Parkinson's Disease News - Sat, 10 Jan 2015 08:58

FDA Approves Rytary Extended-Release for Parkinson's
Neurology Advisor - Thu, 08 Jan 2015 09:39


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014